SAN FRANCISCO and SUZHOU, China, Feb. 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

The release of Phase III Stage 1 data for gotistobart (BNT316/ONC-392) at NACLC 2025 marks one of the most significant developments in CTLA-4–targeted therapy in recent years.

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last week is offset by a challenging tolerability profile. Analysts got an ...

Cadonilimab's ability to target both PD-1 and CTLA-4, two key immune checkpoints, demonstrates its synergistic anti-tumor mechanisms, further demonstrating Akeso's leadership in the global bispecific ...

HONG KONG, June 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's ...

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and ...

27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels of ...

The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...

26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ...